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PURPOSE. To investigate fundus autofluorescence lifetime features in patients with
hydroxychloroquine (HCQ) retinopathy, and to identify early markers of retinal alterations
in patients due to HCQ.
METHODS. Patients attending screening for HCQ retinopathy were imaged with a fluorescence
lifetime imaging ophthalmoscope. Mean retinal fluorescence lifetimes (Tm) were obtained in
a short spectral channel (SSC, 498–560 nm) and a long spectral channel (LSC, 560–720 nm).
Screening modalities included fundus images, fundus autofluorescence intensity images
(FAF), spectral-domain optical coherence tomography (SD-OCT), visual fields, and multifocal
electroretinogram (mfERG).
RESULTS. Forty-two eyes of 21 patients on HCQ therapy and 40 eyes of 20 healthy age-matched
controls were included. Fourteen eyes of 7 patients with HCQ retinopathy (mean age, 66.1
[SD, 7.7] years) and 28 eyes of 14 patients (mean age, 46.1 [SD, 7.9] years) receiving HCQ
without retinopathy were identified. Patients with HCQ retinopathy showed a parafoveal ring-
shaped or oval area of prolonged mean fluorescence lifetimes. In these areas, mean (6SEM)
lifetimes were 374 6 7 ps in the SSC, and on average 19.4% longer compared to the control
group (P ¼ 0.0001). Patients on HCQ without retinopathy had retinal fluorescence lifetimes
that were similar to the control group.
CONCLUSIONS. This study shows that HCQ retinopathy displays characteristic mean
fluorescence lifetimes.
Keywords: FLIO, fluorescence lifetimes, fundus autofluorescence, ophthalmic imaging,
chloroquine, hydroxychloroquine, retinopathy, retinal toxicity
Chloroquine (CQ) and hydroxychloroquine (HCQ) arecommonly used in the management of a variety of
autoimmune disorders, including in the treatment of rheuma-
toid arthritis and systemic lupus erythematosus. Despite having
fewer systemic side effects in comparison to other medications,
CQ and HCQ have been associated with significant retinotox-
icity, which can lead to irreversible central visual loss, color
vision impairment, and visual field defects.1–3 Although the
exact pathophysiological mechanisms of retinal toxicity are still
not fully understood, HCQ toxicity occurs far more frequently
than originally contemplated. It is estimated that 7.5% of
patients are affected after 5 years of treatment.4 The most
important risk factors predisposing to the development of HCQ
retinopathy are long-term HCQ therapy (duration > 5 years of
use), higher doses (>5.0 mg/kg), concomitant renal disorders,
and use of tamoxifen.2–4
Early detection of CQ retinopathy is vital as the damage can
progress even after cessation of the drug due to the slow
clearance of the medication from the body.5,6 Thus, screening
for early retinal toxicity is crucial to detect signs of
maculopathy at a ‘‘preclinical phase’’ to prevent severe visual
loss via early discontinuation of the medication. The American
Academy of Ophthalmology recommends routinely performing
an ophthalmologic examination and automated threshold visual
field testing with a white 10-2 pattern, along with at least one
objective imaging modality such as multifocal electroretino-
gram (mfERG), fundus autofluorescence (FAF), or spectral-
domain optical coherence tomography (SD-OCT). These
examinations should be performed at baseline and annually at
each visit after 5 years of HCQ use.7
Recent technological advancements have shown that subtle
changes in cellular metabolism in different metabolic condi-
tions can be identified using fluorescence lifetime imaging
microscopy (FLIM).8 Fluorescence lifetime imaging ophthal-
moscopy (FLIO), an in vivo FLIM method, is a novel
noninvasive imaging modality currently in clinical use to
identify and quantify metabolic abnormalities in retinal diseases
by imaging lifetimes of endogenous retinal fluorophores.9–13
The fluorescence lifetime represents the time span an intrinsic
fluorophore spends in a higher energy level following an
excitation with a blue laser before returning to its ground level
by releasing a photon with a longer emission wavelength.
The aim of this study was to evaluate and characterize
retinal fluorescence lifetimes (FLT) using the mean lifetime
(Tm) in patients with CQ retinopathy and in patients using
HCQ with currently no evidence of toxicity.
METHODS
This prospective case–control study was performed at the
ophthalmology outpatient department of the University Hospi-
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tal in Bern, Switzerland, with the approval of the local ethics
committee and in accordance with the Declaration of Helsinki.
An informed consent was signed prior to study entry.
For each participant a standardized sequence of investiga-
tions was performed including a general ophthalmologic
examination with measurement of the best-corrected visual
acuity (Snellen chart).10 Pupils were dilated with tropicamide
0.5% and phenylephrine HCl 2.5%. In both eyes, fundus color
images (Zeiss FF 450plus; Zeiss, Oberkochen, Germany),
optical coherence tomography (OCT) scans of the macula
(Heidelberg Spectralis HRAþOCT; Heidelberg Engineering,
Heidelberg, Germany), Octopus 10-2 visual fields, FAF images,
and fluorescence lifetime images were obtained. Multifocal
electroretinogram (mfERG) was performed in cases with HCQ
retinopathy.
The diagnosis of HCQ retinopathy was made if abnormal-
ities were detected on clinical examination, Octopus 10-2
visual fields, multifocal ERG, SD-OCT, and/or FAF. Patients with
HCQ retinopathy were separated into early, obvious, and
severe cases of toxicity. The early group consisted of eyes with
no disruption of the ellipsoid zone (EZ) in the foveal and
parafoveal area on SD-OCT. On fundus examination, no or early
macular findings were identified. The obvious group com-
prised eyes presenting the classic parafoveal retinal pigment
epithelium (RPE) changes with a disrupted parafoveal EZ on
either one or both sides of the fovea, and an intact foveal EZ.
The severe group included only eyes with clear foveal and
parafoveal EZ disruption.
All patients were selected from patients being treated for
rheumatic conditions, such as systemic lupus erythematosus,
Sjogren’s disease, and rheumatoid arthritis. Clinical data
including the daily dose, duration of drug exposure, and a
cumulative dose were recorded. Eyes with neovascular age-
related macular degeneration, diabetic retinopathy, significant
lens opacities, and other ophthalmic diseases affecting the
macula were excluded.
Participants were divided into one of two groups: HCQ
retinopathy, or on HCQ therapy without clinical evidence of
retinopathy. Each group was compared to a healthy age-
matched control group with no history of HCQ use.
This s tudy is reg is te red at Cl in ica lTr ia l s .gov
(NCT01981148).
Fluorescence Lifetime Imaging Ophthalmoscope
Fluorescence lifetime data were obtained using the fluores-
cence lifetime imaging ophthalmoscope, based on a Heidel-
berg retina angiograph (HRA) Spectralis system.
A 473-nm pulsed laser at 80-MHz repetition rate was used to
excite retinal autofluorescence. Emitted photons were record-
ed in a short spectral channel (498–560 nm, SSC) and a long
spectral channel (560–720 nm, LSC) using highly sensitive
hybrid photon-counting detectors (HPM-100-40; Becker&Hickl,
Berlin, Germany), and time-correlated single-photon counting
(TCSPC) modules (SPC-150; Becker&Hickl). At least 1000
photons per pixel were recorded within the macular center. To
guarantee correct allocation of the detected photons, a built-in
infrared scanning laser ophthalmoscope image was used. In
addition, the near-infrared image was used to align the FLIO
images.
Within the central 308 of the macula, a decay trace was built
from the recorded single photons, and a biexponential decay
function was calculated using a binning factor of 1. The
double-exponential estimate of the fluorescence decay curve
calculated a mean decay trace that is characterized by a short
(T1) and a long (T2) decay component, along with their
relative amplitudes a1 and a2. The mean fluorescence lifetime
(Tm) represents the amplitude-weighted mean fluorescence
decay time per pixel and wavelength channel, which was
determined by the tau values T1 and T2, and the amplitudes a1
and a2. The theories and technical details behind FLIO have
been described in more detail in previous publications.9–13
Analysis of Fluorescence Lifetime Data
The FLIO reader software (ARTORG Center for Biomedical
Engineering Research, University of Bern, Switzerland) was
used to analyze fluorescence lifetime data.
The short and the long spectral channels were analyzed
separately. Retinal autofluorescence lifetimes were quantified
within the standard Early Treatment Diabetic Retinopathy
Study (ETDRS) grid with the following measurements: central
area (diameter [d] ¼ 1 mm), inner ring (d ¼ 3 mm), and outer
ring (d ¼ 6 mm).10
Analysis of OCT Data
OCT images were analyzed in the foveal and parafoveal region
for decreased reflectivity of the EZ, EZ disruption, interdigita-
tion zone (IZ) disruption, RPE disruption, and external limiting
membrane (ELM) disruption, as well as thinning of the outer
nuclear layer (ONL).
Statistical Analysis
All data are presented as mean 6 standard error of the mean
(SEM). Prism GraphPad (Prism 6; GraphPad Software, Inc., La
Jolla, CA, USA) was used for statistical analysis. The D’Agostino-
Pearson normality test was performed and a t-test was used to
compare lifetime values between cohorts. Results were
averaged from both eyes in each subject before group statistics
were performed. Pearson correlation coefficient was used to
analyze the correlation between the continuous variables. P
values of less than 0.05 were considered to be statistically
significant.
RESULTS
The demographic characteristics and clinical features of the 21
included HCQ patients are shown in Table 1. All participants
were Caucasian, phakic with clear media, and had no
concomitant ophthalmic diseases.
Seven patients (14 eyes) showed definite HCQ retinopathy,
and 14 patients (28 eyes) were on HCQ treatment but with no
TABLE 1. Comparison of Characteristics Between Patients With and
Without Retinal Toxicity
Variable
Chloroquine
Retinopathy, n ¼ 7
Chloroquine
Use, n ¼ 14
Patient characteristics,
No.
Female, n 5 12
Age, y (range) 68.7 6 7.9 (51–75) 46.1 6 7.7 (34–57)
Primary indication,
No. (%)
Lupus erythematosus 3 (42.8) 9 (64.3)
Polyarthritis 1 (14.3) 1 (7.1)
Rheumatoid arthritis 1 (14.3) 2 (14.3)
Sjo¨gren syndrome 1 (14.3) 1 (7.1)
Folliculitis decalvans 1 (14.3) 0 (0)
Drug use
Cumulative use, g 920.1 6 129.2 462.7 6 113
Duration of use, y 14.4 6 9.7 5.0 6 5.3
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clinical abnormalities. Between the two groups, significant
differences included the mean age (68.7 6 SD 7.9 years in eyes
with HCQ retinopathy and 46.1 6 SD 7.7 in those without
retinopathy, P < 0.0001), mean duration of HCQ use (14.4 6
9.7 vs. 5.0 6 1.5 years, P¼ 0.0048), and cumulative HCQ dose
(920.1 6 129.2 vs. 462.7 6 113 g, P ¼ 0.002). The HCQ
retinopathy group included eight eyes (58.1%) with retinopa-
thy displaying the classic bull’s-eye maculopathy and six eyes
(42.9%) with early retinopathy.
Patients were compared to a total of 20 healthy controls
with no history of HCQ use; each analyzed group included 20
eyes of 10 age-matched subjects (mean age 6 SD: 68.7 6 5.4
years for eyes with HCQ retinopathy and 46.4 6 6.3 years for
those without retinopathy).
Fluorescence Lifetimes in Patients With
Hydroxychloroquine Retinopathy and Healthy
Controls
The fundus of healthy eyes revealed normal fluorescence
lifetime patterns with a gradual prolongation of lifetimes from
the center outward. Patients with HCQ retinopathy displayed a
pericentral ring of prolonged mean fluorescence lifetimes,
which varied from a half to a complete ring-shaped lesion.
Generally, the disease-specific distinctive fluorescence lifetime
changes were more pronounced in the SSC; thus for
simplification we focused on the SSC in this study. All patients
with clinically diagnosed HCQ retinopathy displayed charac-
teristic disease features in fundus photography, OCT, and FAF
imaging (Fig. 1).
In both healthy controls and patients with HCQ retinopathy,
the shortest fluorescence lifetimes were measured within the
macular center (Fig. 2). However, patients with HCQ
retinopathy displayed significantly longer mean fluorescence
lifetimes within the central subfield of the ETDRS grid
compared to control eyes (SSC: 295 6 22 vs. 229 6 15.3 ps,
P¼0.002). Furthermore, in patients with HCQ retinopathy, the
mean lifetime values Tm within the inner ring of the ETDRS
grid were significantly prolonged in comparison to the control
subjects (SSC: 374 6 7 vs. 313 6 8 ps, P¼ 0.0001) (Table 2).
Thereby, Tm was lengthened by 19.4% in patients with HCQ
retinopathy in the SSC. In areas of structurally unaffected retina
within the outer ETDRS ring, fluorescence lifetime values in
patients with HCQ retinopathy were comparable with those of
healthy age-matched controls (P ¼ 0.195). There was no
significant difference in lifetime measurements between the
right and left eyes (paired t-test, P ¼ 0.8219).
We analyzed differences in autofluorescence lifetimes
between healthy participants and patients with HCQ retinop-
athy at different severity grades. Disease severity was graded as
early in 4% of eyes (six), obvious in 50% of eyes (seven), and
severe in 7% of eyes (one). In OCT, patients with obvious and
severe HCQ retinopathy manifested with a disruption or
complete parafoveal loss of ONL, ELM, EZ, and disruption of
the underlying RPE layer within the parafoveal region, which
corresponded to areas of prolonged mean fluorescence
lifetimes. In the severe and obvious cases, a parafoveal
concentric ring or crescent ring-shaped area showed a mottled
loss of FAF, which correlated to prolonged lifetimes. The
typical ‘‘flying saucer’’ sign was observed in patients with
preservation of the central subfoveal architecture and a
perifoveal loss of the outer retinal tissue (Fig. 3).
In four eyes with early HCQ retinopathy, FLIO demonstrat-
ed a subtle perifoveal ring of prolonged lifetimes. Patients were
found to have a completely normal fundus exam and FAF;
however, OCT demonstrated a minor loosening of the
photoreceptor layer with thinning of the ONL (Fig. 4).
FIGURE 1. Fluorescence lifetime images (FLIO, short spectral channel [SSC], 498–560 nm), fundus autofluorescence image (FAF), in a healthy
subject (control, top row), a patient with hydroxychloroquine (HCQ) retinopathy (middle), and a patient on HCQ therapy (below). Corresponding
optical coherence tomography (OCT) scan of a horizontal scan through the macula is shown also.
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The mean retinal thickness of the inner EDTRS ring was
significantly reduced in patients with HCQ retinopathy
compared to patients currently on therapy, as well as healthy
controls (259.5 6 5.9 vs. 341.5 6 5.9, vs. 335.8 6 5.5 lm;
both P < 0.0001). The mean retinal thickness showed no
significant correlation with mean fluorescence lifetimes (r2 ¼
0.189, P ¼ 0.329).
Fluorescence Lifetimes in Patients on Chloroquine
Therapy Without Retinopathy
Eyes in the HCQ group without retinopathy showed no specific
findings on FAF imaging, and OCT-scan images showed
structurally intact photoreceptors and a RPE/Bruch’s membrane.
Quantitative analysis of mean fluorescence lifetimes revealed no
significant difference between patients on HCQ therapy com-
pared to the corresponding area in the control eyes (Fig. 2). This
was observed in both the subgroup receiving HCQ treatment ‡5
years and in the subgroup treated with HCQ <5 years.
The difference between mean retinal thickness of the inner
ring in patients on HCQ therapy compared to healthy controls
was insignificant (341.5 6 5.9 vs. 338.2 6 5.6 lm; P¼ 0.155)
(Table 2).
Cumulative Dose and Mean Fluorescence Lifetimes
Regression analyses were performed to evaluate the correlation
between the cumulative dose and the mean fluorescence
lifetimes (Fig. 5). Mean fluorescence lifetime values within the
inner ring of the ETDRS grid in the SSC correlated with the
cumulative HCQ dosage (r2¼ 0.35, P¼ 0.026). In this analysis,
in eyes of patients on current HCQ treatment with no clinical
evidence of retinopathy, a weak correlation between the
cumulative dose and mean fluorescence lifetime values was
identified (r2 ¼ 0.17, P ¼ 0.048).
FIGURE 2. (A) Quantitative analysis of retinal autofluorescence lifetimes (FLIO) in patients with hydroxychloroquine (HCQ) retinopathy (severity¼
obvious) and (B) in patients on HCQ therapy without retinopathy. Mean fluorescence lifetime values, with error bars (SEM), were evaluated within
the ETDRS grid shown (diameter central area C¼ 1 mm, inner ring IR¼ 3 mm, outer ring OR¼ 6 mm). Mean values from the SSC were compared
with the healthy retina within the central area, inner and outer ETDRS ring. ns, not significant.
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Analysis of Individual Fluorescence Lifetime
Components
A two-dimensional (2-D) histogram allows in-depth analysis of
the amplitude-weighted mean fluorescence lifetime value, Tm,
by separately representing its two single components, T1
(short decay component) on the x-axis and T2 (long decay
component) on the y-axis.
Thereby, the fovea featured the shortest T1, combined with
short T2 values, in all cohorts. The lifetime cloud of areas with
photoreceptor atrophy in patients with HCQ retinopathy
revealed longer T1 and T2 values than the surrounding retina.
In patients currently on HCQ therapy without retinopathy, no
differences in the lifetime clouds was observed in comparison
to healthy controls. The optic nerve head featured the longest
T2 values in all cohorts (Fig. 6).
DISCUSSION
Over the past decade, advancements in retinal imaging,
histologic studies, and animal experiments have increased
our understanding of pathological features of CQ/HCQ
retinopathy. However, as clinical changes can be subtle,
particularly in early stages of disease, and can lead to
irreversible visual impairments, imaging techniques are needed
to identify alterations at an earlier stage. Within the field of
retinal imaging, FLIO is a relatively novel imaging modality
with the ability to identify subtle alterations within the retina,
and to provide further information in addition to conventional
retinal imaging techniques.9–11,14,15
The mechanism by which CQ/HCQ causes retinal toxicity is
not well established; however, the outer retina, specifically the
photoreceptors and RPE, have been proposed to play a major
role.16–18 Previous studies have shown that both CQ and HCQ
FIGURE 3. Correlation of fluorescence lifetime findings with optical
coherence tomography (OCT). Color fundus (CF), infrared (IR), FAF
intensity, autofluorescence lifetime images (FLIO, SSC¼ 498–560 nm),
and OCT of the indicated green line in the FAF and IR images. Areas of
long fluorescence lifetimes (green) in FLIO corresponded to areas of
RPE atrophy with the absence of ONL, EZ, IZ, and intraretinal
hyperreflective deposits (marked with blue arrowheads).
FIGURE 4. Multimodal imaging of one eye of a patient with early HCQ
retinopathy showing a parafoveal ring of prolonged lifetimes. Fundus
photography (CF), FAF image, fluorescence lifetime images in the SSC
(FLIO, SSC); and SD-OCT horizontal scan of the indicated green line in
the FAF image.
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may interfere in the visual cycle by inhibiting the uptake
activity of an organic anion transporting polypeptide, 1A2
(OATP1A2), found in the RPE. This is in agreement with the
proposed accumulation of the medication in ocular tissues,
such as the RPE, choroid, ciliary body, and iris, and in the
retina.19 The accumulation of the medication at the level of the
RPE may explain why further progression of the retinopathy
can occur even after cessation of the drug.20,21 Consequently,
outer retinal and photoreceptor degeneration with subse-
quent, secondary deterioration of the RPE may occur, which
can be observed on OCT. While it remains unknown why the
para- and perifoveal area of photoreceptors are most prone to
the toxic effects of HCQ observed clinically and demonstrated
in histology, it has been suggested that the difference in
concentration between foveal and pericentral cones may be
responsible.22,23
In this prospective study, we investigated retinal fluores-
cence lifetimes in 14 eyes of 7 patients with HCQ retinopathy,
and in 28 eyes of 14 patients currently on HCQ therapy using
autofluorescence FLIO. In our study, patients with HCQ
retinopathy displayed characteristic mean fluorescence life-
time patterns. Fluorescence lifetime imaging illustrated that the
HCQ toxicity localizes in the parafoveal area, in the typical
bulls-eye distribution with prolongation of retinal fluorescence
lifetimes.
While at early stages in HCQ retinopathy retinal pigment
epithelial abnormalities were identified as a fine paracentral
ring of prolonged lifetimes, in more advanced cases, the circle
of prolonged lifetimes appeared to broaden and become more
distinct, which corresponded to the severity of OCT changes.
In early HCQ toxicity, the fine paracentral ring of prolonged
lifetimes correlated to loosening of the photoreceptor layer
and outer retinal abnormalities including the disruption of the
IZ, with or without a disruption of the of EZ. This finding
confirms results of a previous study in patients with retinitis
pigmentosa, where areas of preserved RPE in the presence of
photoreceptor disruption displayed a ring with prolonged
fluorescence lifetimes in FLIO.24
In more obvious and advanced stages of HCQ retinopathy,
the distinct ring of prolonged lifetimes was measured within
areas of atrophy, which correlated to a diffuse loss of
photoreceptors and RPE with an increased transmission of
FIGURE 5. (A) Correlation of fluorescence lifetimes within the inner ring (IR) of the standard EDTRS grid with mean total cumulative dose in grams.
A correlation index of (A) patients with HCQ retinopathy, r2 ¼ 0.35 (P ¼ 0.026) and (B) HCQ use, r2 ¼ 0.17 (P ¼ 0.048) was measured. (B)
Representative fluorescence lifetime (FLIO, SSC) images of the three severity groups, early (green), obvious (orange), severe (red), with correlating
OCT scan of the indicated lines in the FLIO images.
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the OCT signal to the choroid. This is in keeping with previous
fluorescence lifetime reports of patients with geographic
atrophy, Stargardt disease, retinitis pigmentosa, and choroide-
remia, where prolonged lifetimes were identified within areas
of photoreceptor and RPE atrophy.9,11,24
We can only speculate about the provenience of the
observed prolonged fluorescence lifetimes. Because areas with
long fluorescence lifetimes are congruent with areas of
hypoautofluorescence in FAF (Fig. 3), a contribution of
lipofuscin can be excluded. On the other hand, long
fluorescence lifetimes may be explained by loss of photore-
ceptors and a higher contribution of the choroid to observed
lifetimes, similarly to what has been described in patients with
choroideremia.25 One possible, but speculative explanation for
the short fluorescence lifetimes observed could be the
presence of residual visual cycle activity, with or without the
generation of visual cycle by-products, within this border zone
between the unaffected retina and the RPE atrophy.26,27
Plotting individual lifetime components, such as T1 and T2
on the 2-D histogram (Fig. 6), allows visualization of specific
retinal areas, such as the perifoveal area. In addition, areas with
atrophy can be visualized. This tool may be used for
quantification of atrophic changes in follow-up examinations
and longitudinal studies.
This study had several limitations. Because the general
consensus is that HCQ mainly targets the parafovea area, we
considered only structural and functional characterization
related to the central macular area.7,28 However, this may not
be applicable for all patients, as numerous reports have
confirmed that in Asian populations, for example, a more
pericentral retinopathy, extending to the vascular arcades, is
observed.29 As our study population consisted solely of
Caucasians of European descent, in which the peripheral
phenotype has been documented in only 2% of cases, no
significant results bias is expected.29 Furthermore, as FLIO has
been shown to be influenced by opacities in the optical axis,
especially in the short spectral channel, we cannot exclude
that some of the observed changes in our study were caused by
imaging artifacts. Larger cohorts will be required to evaluate
characteristic lifetime patterns in patients with HCQ retinop-
FIGURE 6. Analysis of individual lifetime components and spatial distribution in patients with definite HCQ retinopathy. Color fundus (CF), FAF
intensity, and mean fluorescence lifetime (Tm, SSC) images. Corresponding distribution histograms of the short decay component T1 versus the
long decay component T2 are shown. Spatial distribution of different lifetime clusters as follows: (1) fovea with short T1 and short T2; (2)
surrounding retina with short T1 and midrange T2; and (3) atrophy with long T1 and long T2.
TABLE 2. Comparison of Mean Fundus Autofluorescence Lifetimes (6SD) Within the ETDRS Areas Between Subjects on HCQ Therapy and a
Control Group Without HCQ
ETDRS Central Inner Ring Outer Ring
HCQ retinopathy group, n ¼ 7 295.2 6 34.4 374.4 6 26.7 348.3 6 29.4
Control group, n ¼ 20 229.2 6 33.8 313.5 6 20.1 329.0 6 28.1
P value 0.002 0.0001 0.19
HCQ therapy group, n ¼ 14 193.1 6 39.1 273.0 6 31.2 302.3 6 13.6
Control group, n ¼ 20 163.3 6 33.1 255.0 6 19.9 290.2 6 13.9
P value 0.11 0.15 0.07
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athy. In addition, to gain further insight into the long-term
effects of HCQ therapy in patients with no clinical evidence of
retinopathy, a larger population of patients on HCQ for over 5
years will be required. Longitudinal follow-up examinations of
the patients currently taking HCQ and further correlation with
functional parameters are currently under way to identify
markers for disease progression.
This study established that HCQ retinopathy displays a
characteristic mean fluorescence lifetime pattern. In patients
currently on HCQ therapy with no clinical retinopathy,
lifetimes were comparable to those of age-matched controls,
suggesting that in HCQ retinopathy, FLIO is not yet able to
detect metabolic changes before structural damage occurs.
However, in this study we established that the FLIO technique
in general might be helpful to detect, quantify, and monitor for
retinal changes in patients taking HCQ.
Acknowledgments
Supported by Heidelberg Engineering GmBH, Germany.
Disclosure: Y. Solberg, None; C. Dysli, None; B. Mo¨ller, None; S.
Wolf, Allergan (C), Bayer (C) Novartis (C), Heidelberg Engineering
(F, C), Zeiss (C), Chengdu Kanghong (C); M.S. Zinkernagel,
Allergan (C), Bayer (F, C), Novartis (C, I), Heidelberg Engineering
(F)
References
1. Rynes RI. Antimalarial drugs in the treatment of rheumato-
logical diseases. Br J Rheumatol. 1997;36:799–805.
2. Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF; American
Academy of Ophthalmology. Revised recommendations on
screening for chloroquine and hydroxychloroquine retinopa-
thy. Ophthalmology. 2011;118:415–422.
3. Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF;
American Academy of Ophthalmology. Recommendations
on screening for chloroquine and hydroxychloroquine
retinopathy (2016 revision). Ophthalmology. 2016;123:
1386–1394.
4. Melles RB, Marmor MF. The risk of toxic retinopathy in
patients on long-term hydroxychloroquine therapy. JAMA
Ophthalmol. 2014;132:1453–1460.
5. Brinkley JR Jr, Dubois EL, Ryan SJ. Long-term course of
chloroquine retinopathy after cessation of medication. Am J
Ophthalmol. 1979;88:1–11.
6. Mavrikakis M, Papazoglou S, Sfikakis PP, Vaiopoulos G, Rougas
K. Retinal toxicity in long term hydroxychloroquine treat-
ment. Ann Rheum Dis. 1996;55:187–189.
7. Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF;
American Academy of Ophthalmology. Recommendations on
screening for chloroquine and hydroxychloroquine retinopa-
thy: a report by the American Academy of Ophthalmology.
Ophthalmology. 2002;109:1377–1382.
8. Becker W. Fluorescence lifetime imaging–techniques and
applications. J Microsc. 2012;247:119–136.
9. Dysli C, Wolf S, Hatz K, Zinkernagel MS. Fluorescence lifetime
imaging in Stargardt disease: potential marker for disease
progression. Invest Ophthalmol Vis Sci. 2016;57:832–841.
10. Dysli C, Wolf S, Berezin MY, Sauer L, Hammer M, Zinkernagel
MS. Fluorescence lifetime imaging ophthalmoscopy. Prog
Retin Eye Res. 2017;60:120–143.
11. Dysli C, Wolf S, Zinkernagel MS. Autofluorescence lifetimes in
geographic atrophy in patients with age-related macular
degeneration. Invest Ophthalmol Vis Sci. 2016;57:2479–
2487.
12. Sauer L, Klemm M, Peters S, et al. Monitoring foveal sparing in
geographic atrophy with fluorescence lifetime imaging
ophthalmoscopy - a novel approach. Acta Ophthalmol.
2018;96:257–266.
13. Sauer L, Gensure RH, Hammer M, Bernstein PS. Fluorescence
lifetime imaging ophthalmoscopy: a novel way to assess
macular telangiectasia type 2. Ophthalmol Retina. 2018;2:
587–598.
14. Dysli C, Quellec G, Abegg M, et al. Quantitative analysis of
fluorescence lifetime measurements of the macula using the
fluorescence lifetime imaging ophthalmoscope in healthy
subjects. Invest Ophthalmol Vis Sci. 2014;55:2106–2113.
15. Dysli C, Wolf S, Zinkernagel MS. Fluorescence lifetime
imaging in retinal artery occlusion. Invest Ophthalmol Vis
Sci. 2015;56:3329–3336.
16. Kellner S, Weinitz S, Kellner U. Spectral domain optical
coherence tomography detects early stages of chloroquine
retinopathy similar to multifocal electroretinography, fundus
autofluorescence and near-infrared autofluorescence. Br J
Ophthalmol. 2009;93:1444–1447.
17. Marmor MF. Comparison of screening procedures in hydroxy-
chloroquine toxicity. Arch Ophthalmol. 2012;130:461–469.
18. Rodriguez-Padilla JA, Hedges TR III, Monson B, et al. High-
speed ultra-high-resolution optical coherence tomography
findings in hydroxychloroquine retinopathy. Arch Ophthal-
mol. 2007;125:775–780.
19. Rosenthal AR, Kolb H, Bergsma D, Huxsoll D, Hopkins JL.
Chloroquine retinopathy in the rhesus monkey. Invest
Ophthalmol Vis Sci. 1978;17:1158–1175.
20. de Sisternes L, Hu J, Rubin DL, Marmor MF. Localization of
damage in progressive hydroxychloroquine retinopathy on
and off the drug: inner versus outer retina, parafovea versus
peripheral fovea. Invest Ophthalmol Vis Sci. 2015;56:3415–
3426.
21. Mititelu M, Wong BJ, Brenner M, Bryar PJ, Jampol LM, Fawzi
AA. Progression of hydroxychloroquine toxic effects after
drug therapy cessation: new evidence from multimodal
imaging. JAMA Ophthalmol. 2013;131:1187–1197.
22. Bernstein HN, Ginsberg J. The pathology of chloroquine
retinopathy. Arch Ophthalmol. 1964;71:238–245.
23. Wetterholm DH, Winter FC. Histopathology of chloroquine
retinal toxicity. Arch Ophthalmol. 1964;71:82–87.
24. Dysli C, Schurch K, Pascal E, Wolf S, Zinkernagel MS. Fundus
autofluorescence lifetime patterns in retinitis pigmentosa.
Invest Ophthalmol Vis Sci. 2018;59:1769–1778.
25. Dysli C, Wolf S, Tran HV, Zinkernagel MS. Autofluorescence
lifetimes in patients with choroideremia identify photorecep-
tors in areas with retinal pigment epithelium atrophy. Invest
Ophthalmol Vis Sci. 2016;57:6714–6721.
26. Sparrow JR, Fishkin N, Zhou J, et al. A2E, a byproduct of the
visual cycle. Vision Res. 2003;43:2983–2990.
27. Sparrow JR, Marsiglia M, Allikmets R, et al. Flecks in recessive
Stargardt disease: short-wavelength autofluorescence, near-
infrared autofluorescence, and optical coherence tomogra-
phy. Invest Ophthalmol Vis Sci. 2015;56:5029–5039.
28. Yusuf IH, Sharma S, Luqmani R, Downes SM. Hydroxychlor-
oquine retinopathy. Eye (Lond). 2017;31:828–845.
29. Lee DH, Melles RB, Joe SG, et al. Pericentral hydroxychlor-
oquine retinopathy in Korean patients. Ophthalmology. 2015;
122:1252–1256.
FLIO in HCQ Retinopathy IOVS j May 2019 j Vol. 60 j No. 6 j 2172
Downloaded from iovs.arvojournals.org on 09/18/2019
